NICE Recommends Biosimilar Infliximab For RA
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, looks set to recommend biosimilar versions of Merck's Remicade (infliximab) – Napp's Remsima and Hospira's Inflectra – as well as the originator, for some NHS patients with rheumatoid arthritis.